Curious if anyone is familiar with the science on this... E.L. is looking to run clinical trials of Eloralintide in combination with Tirzepatide and/or Retatrutide which would theoretically/hopefully be a killer combo and I know a lot of us here are looking to do that combo.
But here's my question - with Eloralintide being more complicated/difficult to manufacture (and subsequently for gray marketeers to test) would it be possible to combine the two in one solution?
For example, I'm trying to figure out what Novo is doing here:
https://www.fiercebiotech.com/biotech/novo-ceo-insists-no-change-plan-cagrisema-launch-after-single-chamber-device-ditched
"Novo had also been working on a co-formulation version that could have potentially allowed for CagriSema to be administered in a single-chamber device. However, the company revealed in its first-quarter earnings documents (PDF) Wednesday that it has terminated this co-formulation project “due to portfolio considerations.”
Just more complicated for them to bother combining when they can manufacture each separately at a lower cost? Is that the right read there? Not that it's technically impossible, just that it's cheaper for them to manufacture separately and then offer a double-chambered injector device?
Guess I'm trying to figure out just how complicated Elora is as a whole - I don't personally care if I had to take separate shots and it would generally be better for most of us anyway because you could tweak each dose to your liking.
But here's my question - with Eloralintide being more complicated/difficult to manufacture (and subsequently for gray marketeers to test) would it be possible to combine the two in one solution?
For example, I'm trying to figure out what Novo is doing here:
https://www.fiercebiotech.com/biotech/novo-ceo-insists-no-change-plan-cagrisema-launch-after-single-chamber-device-ditched
"Novo had also been working on a co-formulation version that could have potentially allowed for CagriSema to be administered in a single-chamber device. However, the company revealed in its first-quarter earnings documents (PDF) Wednesday that it has terminated this co-formulation project “due to portfolio considerations.”
Just more complicated for them to bother combining when they can manufacture each separately at a lower cost? Is that the right read there? Not that it's technically impossible, just that it's cheaper for them to manufacture separately and then offer a double-chambered injector device?
Guess I'm trying to figure out just how complicated Elora is as a whole - I don't personally care if I had to take separate shots and it would generally be better for most of us anyway because you could tweak each dose to your liking.
.
